Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2012, Article ID 852183, 11 pages
http://dx.doi.org/10.1155/2012/852183
Review Article

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Department of Ophthalmology, Oita University, Faculty of Medicine, Hasama-machi, Yufu-shi, Oita 879-5593, Japan

Received 5 August 2011; Accepted 31 August 2011

Academic Editor: Yoshiaki Kiuchi

Copyright © 2012 Kenichi Kimoto and Toshiaki Kubota. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Google Scholar
  2. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57–65, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. D. Regillo, D. M. Brown, P. Abraham et al., “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. P. Abraham, H. Yue, and L. Wilson, “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 315–324, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 566–583, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. U. Chakravarthy, A. P. Adamis, E. T. Cunningham Jr. et al., “Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 9, pp. 1508–1525, 2006. View at Google Scholar
  8. T. R. Friberg and M. Tolentino, “Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study,” British Journal of Ophthalmology, vol. 94, no. 12, pp. 1611–1617, 2010. View at Publisher · View at Google Scholar · View at PubMed
  9. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at PubMed
  10. J. S. Heier, D. Boyer, Q. D. Nguyen et al., “The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing,” Ophthalmology, vol. 118, no. 6, pp. 1098–1106, 2011. View at Publisher · View at Google Scholar · View at PubMed
  11. P. A. Campochiaro, G. Hafiz, S. M. Shah et al., “Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator,” Molecular Therapy, vol. 16, no. 4, pp. 791–799, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. F. Spaide, L. K. Chang, J. M. Klancnik et al., “Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion,” American Journal of Ophthalmology, vol. 147, no. 2, pp. 298–306, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. D. J. Pieramici, M. Rabena, A. A. Castellarin et al., “Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions,” Ophthalmology, vol. 115, no. 10, pp. e47–e54, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. M. Brown, P. A. Campochiaro, R. P. Singh et al., “Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, no. 6, pp. 1124–1133, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. P. A. Campochiaro, D. M. Brown, C. C. Awh et al., “Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study,” Ophthalmology, vol. 118, no. 10, pp. 2041–2049, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. P. A. Campochiaro, J. S. Heier, L. Feiner et al., “Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, no. 6, pp. 1102–e1, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. M. Brown, P. A. Campochiaro, R. B. Bhisitkul et al., “Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study,” Ophthalmology, vol. 118, no. 8, pp. 1594–1602, 2011. View at Google Scholar
  18. D. V. Do, U. Schmidt-Erfurth, V. H. Gonzalez et al., “The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema,” Ophthalmology, vol. 118, no. 9, pp. 1819–1826, 2011. View at Publisher · View at Google Scholar · View at PubMed
  19. R. L. Avery, J. Pearlman, D. J. Pieramici et al., “Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,” Ophthalmology, vol. 113, no. 10, pp. 1695–1705, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. J. Bakri, M. J. Donaldson, and T. P. Link, “Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab,” Eye, vol. 20, no. 12, pp. 1474–1475, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. O. Mason, P. A. Nixon, and M. F. White, “Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 142, no. 4, pp. 685–688, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. R. F. Spaide and Y. L. Fisher, “Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage,” Retina, vol. 26, no. 3, pp. 275–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Wu, M. A. Martínez-Castellanos, H. Quiroz-Mercado et al., “Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 1, pp. 81–87, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. L. Avery, “Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment,” Retina, vol. 26, no. 3, pp. 352–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. F. H. Davidorf, J. G. Mouser, and R. J. Derick, “Rapid improvement of rubeosis iridis from a single bevacizumab (avastin) injection,” Retina, vol. 26, no. 3, pp. 354–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Y. Kahook, J. S. Schuman, and R. J. Noecker, “Intravitreal bevacizumab in a patient with neovascular glaucoma,” Ophthalmic Surgery Lasers and Imaging, vol. 37, no. 2, pp. 144–146, 2006. View at Google Scholar · View at Scopus
  27. S. Grisanti, S. Biester, S. Peters, O. Tatar, F. Ziemssen, and K. U. Bartz-Schmidt, “Intracameral bevacizumab for Iris rubeosis,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 158–160, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. Y. Oshima, H. Sakaguchi, F. Gomi, and Y. Tano, “Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 155–158, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. E. Iliev, D. Domig, U. Wolf-Schnurrbursch, S. Wolf, and G. M. Sarra, “Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma,” American Journal of Ophthalmology, vol. 142, no. 6, pp. 1054–1056, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. S. Yazdani, K. Hendi, and M. Pakravan, “Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma,” Journal of Glaucoma, vol. 16, no. 5, pp. 437–439, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. O. Mason, M. A. Albert, A. Mays, and R. Vail, “Regression of neovascular iris vessels by intravitreal injection of bevacizumab,” Retina, vol. 26, no. 7, pp. 839–841, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. S. Yazdani, K. Hendi, M. Pakravan, M. Mahdavi, and M. Yaseri, “Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial,” Journal of Glaucoma, vol. 18, no. 8, pp. 632–637, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. S. Rizzo, F. Genovesi-Ebert, E. Bartolo, A. Vento, S. Miniaci, and G. Williams, “Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 6, pp. 837–842, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. G. Schmidinger, N. Maar, M. Bolz, C. Scholda, and U. Schmidt-Erfurth, “Repeated intravitreal bevacizumab (AvastinÂ) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation,” Acta Ophthalmologica, vol. 89, no. 1, pp. 76–81, 2011. View at Publisher · View at Google Scholar
  35. T. Wakabayashi, Y. Oshima, H. Sakaguchi et al., “Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases,” Ophthalmology, vol. 115, no. 9, pp. 1571–1580, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. Y. Saito, T. Higashide, H. Takeda, E. Murotani, S. Ohkubo, and K. Sugiyama, “Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab,” American Journal of Ophthalmology, vol. 149, no. 6, pp. 964–972, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. Y. Takihara, M. Inatani, T. Kawaji et al., “Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma,” Journal of Glaucoma, vol. 20, no. 3, pp. 196–201, 2011. View at Google Scholar
  38. Y. Saito, T. Higashide, H. Takeda, S. Ohkubo, and K. Sugiyama, “Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma,” Acta Ophthalmologica, vol. 88, no. 1, pp. 96–102, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. E. Chen and C. H. Park, “Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy,” Retina, vol. 26, no. 6, pp. 699–700, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. K. Ishikawa, S. Honda, Y. Tsukahara, and A. Negi, “Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy,” Eye, vol. 23, no. 1, pp. 108–111, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. D. R. Da Lucena, J. A. S. Ribeiro, R. A. Costa et al., “Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study),” British Journal of Ophthalmology, vol. 93, no. 5, pp. 688–691, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. S. Peters, P. Heiduschka, S. Julien et al., “Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab,” American Journal of Ophthalmology, vol. 143, no. 6, pp. 995–1002, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. A. G. Marneros, J. Fan, Y. Yokoyama et al., “Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function,” American Journal of Pathology, vol. 167, no. 5, pp. 1451–1459, 2005. View at Google Scholar · View at Scopus
  44. W. G. Roberts and G. E. Palade, “Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor,” Journal of Cell Science, vol. 108, no. 6, pp. 2369–2379, 1995. View at Google Scholar · View at Scopus
  45. M. H. Dastjerdi, K. M. Al-Arfaj, N. Nallasamy et al., “Topical bevacizumab in the treatment of corneal neovascularization; results of a prospective, open-label, noncomparative study,” Archives of Ophthalmology, vol. 127, no. 4, pp. 381–389, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. Y. Koenig, F. Bock, F. Horn, F. Kruse, K. Straub, and C. Cursiefen, “Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 10, pp. 1375–1382, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. P. I. Vassileva and T. G. Hergeldzhieva, “Avastin use in high risk corneal transplantation,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 12, pp. 1701–1706, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Pe'er, R. Folberg, A. Itin, H. Gnessin, I. Hemo, and E. Keshet, “Vascular endothelial growth factor upregulation in human central retinal vein occlusion,” Ophthalmology, vol. 105, no. 3, pp. 412–416, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. S. E. Moss, R. Klein, and B. E. K. Klein, “Ten-year incidence of visual loss in a diabetic population,” Ophthalmology, vol. 101, no. 6, pp. 1061–1070, 1994. View at Google Scholar · View at Scopus
  51. Y. M. Paulus and R. F. Gariano, “Diabetic retinopathy: a growing concern in an aging population,” Geriatrics, vol. 64, no. 2, pp. 16–20, 2009. View at Google Scholar · View at Scopus
  52. R. Klein, M. D. Knudtson, K. E. Lee, R. Gangnon, and B. E. K. Klein, “The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twentyfive- year incidence of macular edema in persons with type 1 diabetes,” Ophthalmology, vol. 116, no. 3, pp. 497–503, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. Q. D. Nguyen, S. M. Shah, E. Van Anden, J. U. Sung, S. Vitale, and P. A. Campochiaro, “Supplemental oxygen improves diabetic macular edema: a pilot study,” Investigative Ophthalmology and Visual Science, vol. 45, no. 2, pp. 617–624, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. S. A. Vinores, “Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease,” Histology and Histopathology, vol. 12, no. 1, pp. 99–109, 1997. View at Google Scholar
  55. N. L. Derevjanik, S. A. Vinores, W. H. Xiao et al., “Quantitative assessment of the integrity of the blood-retinal barrier in mice,” Investigative Ophthalmology and Visual Science, vol. 43, no. 7, pp. 2462–2467, 2002. View at Google Scholar · View at Scopus
  56. H. Ozaki, H. Hayashi, S. A. Vinores, Y. Moromizato, P. A. Campochiaro, and K. Oshima, “Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates,” Experimental Eye Research, vol. 64, no. 4, pp. 505–517, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar · View at PubMed
  58. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at PubMed
  59. Q. D. Nguyen, S. M. Shah, J. S. Heier et al., “Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study,” Ophthalmology, vol. 116, no. 11, pp. 2175–2181, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. Q. D. Nguyen, S. M. Shah, A. A. Khwaja et al., “Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study,” Ophthalmology, vol. 117, no. 11, pp. 2146–2151, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. Johnson, H. Gong, T. F. Freddo, N. Ritter, and R. Kamm, “Serum proteins and aqueous outflow resistance in bovine eyes,” Investigative Ophthalmology and Visual Science, vol. 34, no. 13, pp. 3549–3557, 1993. View at Google Scholar · View at Scopus
  62. S. Gartner and P. Henkind, “Neovascularization of the iris (Rubeosis iridis),” Survey of Ophthalmology, vol. 22, no. 5, pp. 291–312, 1978. View at Google Scholar · View at Scopus
  63. T. Kubota, A. Tawara, Y. Hata, A. Khalil, and H. Inomata, “Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma,” British Journal of Ophthalmology, vol. 80, no. 8, pp. 750–754, 1996. View at Google Scholar · View at Scopus
  64. S. Peters, P. Heiduschka, S. Julien, K.-U. Bartz-Schmidt, and U. Schraermeyer, “Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye,” British Journal of Ophthalmology, vol. 92, no. 4, pp. 541–544, 2008. View at Publisher · View at Google Scholar · View at PubMed
  65. S. Ishibashi, A. Tawara, R. Sohma, T. Kubota, and N. Toh, “Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection,” Archives of Ophthalmology, vol. 128, no. 12, pp. 1539–1545, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. T. Kubota, R. Aoki, Y. Harada et al., “Trabecular meshwork in neovascular glaucoma eyes after the intravitreal injection of bevacizumab,” British Journal of Ophthalmology, vol. 93, no. 4, pp. 557–558, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. R. I. Kohno, Y. Hata, Y. Mochizuki et al., “Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection,” American Journal of Ophthalmology, vol. 150, no. 2, pp. 223–229, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. O. Sawada, H. Kawamura, M. Kakinoki, T. Sawada, and M. Ohji, “Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy,” Archives of Ophthalmology, vol. 125, no. 10, pp. 1363–1366, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Google Scholar · View at Scopus
  70. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. A. P. Adamis and D. T. Shima, “The role of vascular endothelial growth factor in ocular health and disease,” Retina, vol. 25, no. 2, pp. 111–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Murata, K. Nakagawa, A. Khalil, T. Ishibashi, H. Inomata, and K. Sueishi, “The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas,” Laboratory Investigation, vol. 74, no. 4, pp. 819–825, 1996. View at Google Scholar · View at Scopus
  73. H. Funatsu, H. Yamashita, H. Noma et al., “Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 1, pp. 3–8, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. I. H. L. Wallow and P. S. Geldner, “Endothelial fenestrae in proliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 19, no. 10, pp. 1176–1183, 1980. View at Google Scholar · View at Scopus
  75. H. Ahmadieh, N. Shoeibi, M. Entezari, and R. Monshizadeh, “Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial,” Ophthalmology, vol. 116, no. 10, pp. 1943–1948, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. E. J. Kuiper, F. A. Van Nieuwenhoven, M. D. de Smet et al., “The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy,” PLoS One, vol. 3, no. 7, Article ID e2675, 2008. View at Publisher · View at Google Scholar · View at PubMed
  77. S. Moradian, H. Ahmadieh, M. Malihi, M. Sohellian, M. H. Dehgan, and M. Azarmina, “Intravitreal bevacizumab in active progressive in active progressive proliferative diabetic retinopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1699–1705, 2008. View at Google Scholar
  78. J. F. Arevalo, M. Maia, H. W. Flynn et al., “Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy,” British Journal of Ophthalmology, vol. 92, no. 2, pp. 213–216, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. T. Kubota, H. Morita, N. Tou et al., “Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab,” Retina, vol. 30, no. 3, pp. 468–472, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. H. A. El-Sabagh, W. Abdelghaffar, A. M. Labib et al., “Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications,” Ophthalmology, vol. 118, no. 4, pp. 636–641, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. M. X. Repka, B. Tung, W. V. Good et al., “Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP),” Archives of Ophthalmology, vol. 124, no. 1, pp. 24–30, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. W. S. Gilbert, G. E. Quinn, V. Dobson, J. Reynolds, R. J. Hardy, and E. A. Palmer, “Partial retinal detachment at 3 months after threshold retinopathy of prematurity: long-term structural and functional outcome,” Archives of Ophthalmology, vol. 114, no. 9, pp. 1085–1091, 1996. View at Google Scholar
  83. W. V. Good, J. T. Flynn, A. J. Flach, G. W. Cibis, E. L. Raab, and G. R. Beauchamp, “Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial,” Transactions of the American Ophthalmological Society, vol. 102, pp. 233–250, 2004. View at Google Scholar
  84. E. J. Chung, J. H. Kim, H. S. Ahn, and H. J. Koh, “Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 11, pp. 1727–1730, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. H. A. Mintz-Hittner and R. R. Kuffel, “Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone i or posterior zone II,” Retina, vol. 28, no. 6, pp. 831–838, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. H. Quiroz-Mercado, M. A. Martinez-Castellanos, M. L. Hernandez-Rojas, N. Salazar-Teran, and R. V. P. Chan, “Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity,” Retina, vol. 28, no. 3, pp. S19–S25, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. G. A. Lalwani, A. M. Berrocal, T. G. Murray et al., “Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity,” Retina, vol. 28, no. 3, pp. S13–S18, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. S. Kusaka, C. Shima, K. Wada et al., “Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study,” British Journal of Ophthalmology, vol. 92, no. 11, pp. 1450–1455, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. J. A. Micieli, M. Surkont, and A. F. Smith, “A systemic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity,” American Journal of Ophthalmology, vol. 148, no. 4, pp. 536–543, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. T. Sato, S. Kusaka, H. Shimojo, and T. Fujikado, “Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity,” Ophthalmology, vol. 116, no. 9, pp. 1599–1603, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. N. I. Nonobe, S. Kachi, M. Kondo et al., “Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab,” Retina, vol. 29, no. 5, pp. 579–585, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. H. Nazari, M. Modarres, M. M. Parvaresh, and K. Ghasemi Falavarjani, “Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 12, pp. 1713–1718, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. W. C. Wu, P. T. Yeh, S. N. Chen, C. M. Yang, C. C. Lai, and H. K. Kuo, “Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan,” Ophthalmology, vol. 118, no. 1, pp. 176–183, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. J. Y. Lee, J. B. Chae, S. J. Yang, Y. H. Yoon, and J. G. Kim, “Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 9, pp. 1257–1262, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. Q. V. Hoang, D. F. Kiernan, F. Y. Chau, M. J. Shapiro, and M. P. Blair, “Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment,” Archives of Ophthalmology, vol. 128, no. 8, pp. 1080–1081, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. A. Kychenthal and P. Dorta, “Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity,” Retina, vol. 30, no. 4, pp. S32–S36, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. S. Honda, H. Hirabayashi, Y. Tsukahara, and A. Negi, “Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 7, pp. 1061–1063, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. M. Saint-Geniez, A. S. R. Maharaj, T. E. Walshe et al., “Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors,” PLoS One, vol. 3, no. 11, Article ID e3554, 2008. View at Publisher · View at Google Scholar · View at PubMed
  99. H. G. T. Blaauwgeers, G. M. Holtkamp, H. Rutten et al., “Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation,” American Journal of Pathology, vol. 155, no. 2, pp. 421–428, 1999. View at Google Scholar · View at Scopus
  100. Q. Schwarz, C. Gu, H. Fujisawa et al., “Vascular endothelial growth factor controls neuronal migration and cooperates with SemaSA to pattern distinct compartments of the facial nerve,” Genes and Development, vol. 18, no. 22, pp. 2822–2834, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. M. Sondell, G. Lundborg, and M. Kanje, “Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system,” Journal of Neuroscience, vol. 19, no. 14, pp. 5731–5740, 1999. View at Google Scholar · View at Scopus
  102. K. Nishijima, Y. S. Ng, L. Zhong et al., “Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury,” American Journal of Pathology, vol. 171, no. 1, pp. 53–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. L. Kong, H. A. Mintz-Hittner, R. L. Penland, F. L. Kretzer, and P. Chévez-Barrios, “Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study,” Archives of Ophthalmology, vol. 126, no. 8, pp. 1161–1163, 2008. View at Publisher · View at Google Scholar · View at PubMed